# Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases

> **NCT07570914** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 28 (estimated)

## Conditions studied

- Colorectal Cancer Liver Metastases (CRLM)
- Colorectal Cancer
- Liver Metastasis

## Interventions

- **DRUG:** Liposomal Irinotecan
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine
- **PROCEDURE:** hepatic arterial infusion chemotherapy (HAIC)

## Key facts

- **NCT ID:** NCT07570914
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-30
- **Primary completion:** 2027-05-30
- **Final completion:** 2032-05-30
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570914, "Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07570914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*